Drug intelligence / Profile preview

FOV2501

Development stage: Unknown
Lead developer: Sanofi
Modality: Recombinant Proteins and Enzymes
Administration: Intravitreal

Overview

FOV2501 is a recombinant protein drug candidate developed for the treatment of retinal diseases, particularly retinitis pigmentosa. Its mechanism of action involves stimulation of nucleoredoxin-like protein 1 (NXNL1), which plays a critical role in promoting retinal cone photoreceptor survival by enhancing aerobic glycolysis and facilitating glucose entry into photoreceptors. The drug was originally discovered by a team led by Prof. Jose-Alain Sahel and has been associated with both congenital disorders and eye diseases[2][9][10].

Targets

RdCVF (Rod-derived cone viability factor)

Beyond the preview

Go deeper on FOV2501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FOV2501.

Explore the full profile